Share on StockTwits

Shares of Alcobra (NASDAQ:ADHD) have earned a consensus rating of “Buy” from the eight analysts that are presently covering the company, Stock Ratings Network reports. Two investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $32.29.

Shares of Alcobra (NASDAQ:ADHD) traded down 2.96% during mid-day trading on Wednesday, hitting $20.00. 65,065 shares of the company’s stock traded hands. Alcobra has a 52-week low of $12.04 and a 52-week high of $26.96. The stock’s 50-day moving average is $19.07 and its 200-day moving average is $18.87. The company’s market cap is $273.2 million.

Alcobra (NASDAQ:ADHD) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.57) earnings per share for the quarter, meeting the analysts’ consensus estimate of ($0.57). On average, analysts predict that Alcobra will post $-2.16 earnings per share for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at FBR Capital Markets initiated coverage on shares of Alcobra in a research note on Wednesday. They set a “market perform” rating and a $23.00 price target on the stock. Separately, analysts at Piper Jaffray initiated coverage on shares of Alcobra in a research note on Monday, August 4th. They set an “overweight” rating and a $42.00 price target on the stock. Finally, analysts at Roth Capital initiated coverage on shares of Alcobra in a research note on Friday, August 1st. They set a “buy” rating and a $40.00 price target on the stock.

Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (NASDAQ:ADHD), a common and morbid neuropsychiatric condition in children and adults.

Receive News & Ratings for Alcobra Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.